von Willebrand Factor von Willebrand factor (VWF) is a multimeric plasma glycoprotein that is required for normal hemostasis. It is primarily synthesized in endothelial cells (ECs) from where it is either constitutively secreted or stored as ultra large molecular weight multimers (ULMWM; comprising VWF moieties of 10,000 kD or more) alongside other bioactive molecules in Weibel Palade bodies (WPBs).
1 VWF is also produced in megakaryocytes; however, circulating VWF is almost exclusively derived from ECs. 2, 3 To render the multimers less thrombogenic, a disintegrin-like and metalloprotease with thrombospondin type 1 motifs 13 (ADAMTS13) cleaves VWF at the A2 domain, thereby reducing VWF multimer size.
4
In the circulation, VWF functions as a chaperone of coagulation factor VIII (FVIII) and forms adhesive strings that mediate platelet adhesion and aggregation to sites of vascular damage. 5 In addition to playing an integral role in hemostasis, recent research has revealed that VWF functions in several other important biological processes such as angiogenesis, cell proliferation, and inflammation. 6, 7 Individuals with abnormal or absent VWF are commonly afflicted with excessive bleeding tendencies due to von Willebrand disease (VWD) or acquired von Willebrand syndrome (AVWS), and may be prone to abnormalities in vessel formation, or angiogenesis.
von Willebrand Disease VWD was first described in 1926 by Dr. Erik von Willebrand, when he cared for a family with a severe mucocutaneous bleeding problem. 8 The index case, a 14-year-old female, bled to death during her fourth menstrual period. In the decades since Dr. von Willebrand noted this "pseudohemophilia," developments in hemostasis and molecular genetics have paved the way for significant progress in our understanding of the disease and allowed for the development of effective treatments. It is now recognized that VWD is an autosomally inherited bleeding disorder, affecting approximately 1% of the population, with a 0.1% symptomatic prevalence. 9, 10 The disease arises from defective or dysfunctional VWF, and consequently, patients present with excessive mucocutaneous bleeding, and in some severe cases, spontaneous bleeding into joints and soft tissues.
reflects abnormalities in platelet, collagen, or FVIII binding. 
VWD and Angiodysplasia
Vascular malformations have been documented in VWD patients since the 1960s when Dr. Armand Quick first reported the presence of dilated blood vessels or telangiectasias in the noses of several patients. 17 We now acknowledge that patients with VWD have an increased frequency of angiodysplasia and vessel abnormalities have also been identified in their gastrointestinal (GI) tract, nail bed, prostate, and skin. 16, [18] [19] [20] Moreover, when compared with other bleeding disorders, there is a 99% positive predictive value for VWD when there is a high degree of capillary torquation, dilation, and extravasation of blood.
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This association between angiodysplasia and GI bleeding in VWD patients was first reported in 1976 by Ramsay et al, when they described "gastrointestinal vascular dysplasia as a cause of persistently recurring melena in two VWD patients."
21 Though decades have elapsed since this observation, an effective treatment for GI bleeding still evades researchers and angiodysplasia remains a serious complication for many VWD patients. In fact, recurrent GI bleeding as a result of angiodysplasia is one of the most challenging problems faced by some patients. 9, 17, [22] [23] [24] In the GI tract, the presentation of angiodysplasia most commonly occurs in the cecum and ascending colon, but has also been noted throughout the small intestine and stomach. 25, 26 Patients often present with multiple lesions in the GI tract that are characterized by a fragile vascular network. 27 Disruption of this delicate vascular architecture can result in severe intractable bleeding, often leading to anemia and requiring hospitalization for transfusions of packed red blood cells. 28 Consequently, many VWD patients experience a decrease in quality of life. 28 While GI bleeding is also present in the general population, it is uncommon (prevalence, 0.83%) and the lesions are usually small with a low risk of bleeding.
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The diagnosis of angiodysplasia can be difficult and often requires invasive techniques such as GI endoscopy. Consequently, the exact prevalence of angiodysplasia in VWD is not known. In a retrospective study of VWD patients with occult or angiodysplastic bleeding in the VWD Prophylaxis Network (PN), angiodysplasia was confirmed as the cause of GI bleeding only in one-third of patients. 30 Although multiple diagnostic methods were used, the cause of bleeding remained unexplained in most patients, highlighting the struggle to determine bleeding etiology.
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The incidence of angiodysplasia varies across VWD subtypes in patients where angiodysplasia is confirmed as the main source of bleeding. In a landmark survey of 4,503 VWD patients, Fressinaud and Meyer identified that angiodysplasia was almost exclusively present in patients lacking HMWM of VWF.
9 Specifically, angiodysplasia was reported in 2% of type 2 VWD patients and 4.5% of type 3 VWD patients.
9
Acquired von Willebrand Syndrome AVWS is a rare bleeding disorder due to noninherited structural and/or functional changes in VWF resulting in hemostatic defects. The condition was first described in 1968 in a case study of a patient with lupus erythematosus. 31 In the past few decades, researchers have discovered that AVWS is often caused by lymphoproliferative disorders, cardiovascular defects such as aortic stenosis, or myeloproliferative disorders among other risk factors. 32 These conditions can influence VWF levels and/or function by decreasing synthesis, inhibiting VWF, increasing clearance due to binding of paraproteins, and pathologically increasing fluid shear stress, resulting in increased proteolysis of VWF by ADAMTS13. [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] In many patients, treating the underlying condition, if possible, often restores the normal VWF function and results in improvement or resolution of AVWS.
Heyde's Syndrome
Epistaxis and GI bleeding resulting from angiodysplastic lesions have been reported in individuals with AVWS caused by aortic stenosis and left ventricular assist devices (LVAD). Increased bleeding tendencies in these patientspoint to a direct role for VWF in the development of angiodysplasia.
22,45-49
The association between GI bleeding and aortic stenosis was first described in 1958 by E.C. Heyde in a letter to the New England Journal of Medicine. Heyde recounted that at least 10 patients with calcific aortic stenosis had massive GI bleeding for which he could discover no cause. 50 This triad of conditions, including aortic stenosis, angiodysplasia, and GI bleeding, is now eponymously referred to as Heyde's syndrome (►Fig. 1).
In the early 1990s, Warkentin et al suggested that the link between aortic stenosis and GI bleeding was a deficiency of the largest VWF multimers. 51 In patients with aortic stenosis, elevated shear stress modulates VWF from a globular protein to an elongated one in which the A2 domain is unfolded. 52 This unfolding exposes cryptic exosites to which ADAMTS13 binds and the VWF multimers are more rapidly cleaved. 52 Consequently, patients exhibit a loss of HMWM and develop AVWS. In vitro studies showed that this is often accompanied by abnormalities in platelet adhesion and aggregation. 53 Having an aortic valve replacement normalizes the deficiency of VWF HMWM and results in an improvement in AVWS. 48, 54 King et al reported the cessation of GI bleeding in 93% of patients with aortic stenosis following an aortic-valve replacement.
Treating Angiodysplastic GI Bleeding
The diagnosis and treatment of recurring GI bleeding in VWD is challenging and associated with significant morbidity.
9,22,30
Patients frequently experience intractable bleeding episodes resulting in recurrent hospital admissions and exposure to multiple therapies of limited efficacy. Bleeding episodes can also develop and increase in severity with age.
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Management of GI bleeding can be done via endoscopy or pharmacological methods, but the difficulty in accessing and identifying the angiodysplastic lesions hinders the development and deliverance of effective treatments. 30 While acute management of GI bleeding has been successful with VWF replacement therapy, prophylaxis has been less effective for preventing recurrent GI bleeding. 22, 56 These clinical observations were supported by findings from the VWD PN study, in which prophylaxis was more efficacious at reducing joint bleeding and menorrhagia than GI bleeding. 57 This may be because the recovery of normal VWF levels is insufficient to reduce GI bleeding and normalization of VWF in cellular compartments such as ECs, platelets, and subendothelial matrix is also required. 58 Furthermore, current VWF replacement treatments are plasma derived, and may be less effective in preventing recurrent bleeding episodes due to their relative lack of HMWM. 25 This loss of HMWM results from proteolytic degradation by ADAMTS-13 during the manufacturing process. 59 Given the known association between the development of angiodysplasia and a lack of VWF HMWM, the use of a recombinant VWF replacement product with HMWM and/or even ULMWM could be valuable for the prevention or treatment of recurrent bleeding episodes.
59,60
As VWF replacement therapy is not adequate for preventing recurrent GI bleeding, physicians have attempted alternate treatments. In cases where the angiodysplastic lesions can be identified through endoscopy, embolization of the main vessel in the area and surgical resection can be used to manage bleeding. 24, 61 This is limited, however, in cases with multiple, diffuse lesions throughout the GI tract. 16 Thalidomide is an inhibitor of neoangiogenesis, an effect mediated by suppression of vascular endothelial growth factor (VEGF). The use of this agent has been somewhat successful in treating angiodysplasia with or without VWD, but it has been associated with a high incidence of side effects.
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Atorvastatin is another drug with antiangiogenic properties. When administered at high doses (up to 80 mg daily), it can also be successful in reducing GI bleeding.
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The clinical difficulties in treating patients with GI bleeding and the continued need for an ideal treatment emphasize the importance of further research on the regulation of angiogenesis. Elucidating the association between angiodysplasia and abnormalities in VWF on a cellular and molecular level may point to novel therapeutic targets.
Cellular and Molecular Basis of Angiogenesis
Angiogenesis is the formation of new, functional blood vessels from the existing vasculature. This is an important process in many physiological events such as embryogenesis, wound healing, and the menstrual cycle. Deviations of this highly regulated process can give rise to several pathological conditions such as proliferative retinopathies, rheumatoid arthritis, and tumourigenesis. 65 The dysregulation of angiogenesis is central to the development of angiodysplasia.
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Normally, expansion of the nascent vascular bed arises under hypoxic conditions that require additional vessel growth to satisfy the oxygen requirements of the surrounding tissue. Hypoxia induces signaling through hypoxia-inducible transcription factors (HIFs) that upregulate many angiogenic factors. 67 Chiefly, HIF-1α induces VEGF. 68 VEGF-A is the best characterized member of the VEGF family of molecules. The binding of VEGF-A to its receptor vascular endothelial growth factor receptor-2 (VEGFR-2) initiates an intracellular signaling cascade, prompting EC proliferation and migration toward the hypoxic environment.
69
Stabilization and maturation of the newly formed vessel requires a fine balance of the interactions between proangiogenic and antiangiogenic molecules. 70 Structural integrity is controlled primarily by Angiopoiein-1 (Ang-1) and Angiopoietin-2 (Ang-2) through signaling of the Tie-2 receptor on ECs. Interactions between the extracellular environment (ECM) and ECs are vital for preserving the stability of the newly formed sprout. These interactions are facilitated by cell surface receptors of the integrin family. One member of this family that plays a central role in angiogenesis is integrin αvβ3. This heterodimeric, transmembrane protein is expressed on the surface of ECs and functions as both a pro-and an anti- Fig. 1 Heyde's syndrome refers to the triad of conditions including aortic stenosis, AVWS, and GI bleeding as a result of angiodysplasia. In individuals with aortic valve stenosis, the aortic valve can become narrow causing blood jet. This high flow rate often makes VWF more susceptible to cleavage by ADAMTS13 resulting in the loss of HMWM of VWF and AVWS. Consequently, patients can develop angiodysplasia in the GI tract which can lead to severe and intractable bleeding. ADAMTS13, a disintegrin-like and metalloprotease with thrombospondin type 1 motifs 13; AVWS, acquired von Willebrand syndrome; GI, gastrointestinal; HMWM, high-molecular-weight multimer; VWF, von Willebrand factor.
angiogenic molecules through VEGFR-2 signaling depending on the ECM and ligand bound. 75, 76 Integrin αvβ3 is the bestcharacterized endothelial receptor for VWF, and is significantly upregulated during wound healing, as it can facilitate ligand binding to VEGFR-2.
77,78
Further research is still required on this protein, as its role appears quite complex and variable depending on the ligand bound.
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Over the years, many molecules have been implicated in the process of angiogenesis, and the list continues to grow with the addition of many chemokines, hormones, neuropeptides, and cytokines among others. 80 At every phase of angiogenesis, these molecules work in harmony to prevent pathologic vessel growth. 80, 81 Angiodysplasia can result from an aberration in this delicate balance between proand anti-angiogenic molecules, and the association of VWF with angiogenic mediators like Ang-2 has pointed to a regulatory mechanism for this hemostatic protein in angiogenesis.
VWF Is a Negative Regulator of Angiogenesis
For many years, we have known that VWF defects can play a role in the formation of angiodysplastic lesions. However, the cellular and molecular pathway through which VWF regulates angiogenesis remained relatively unknown until 2011, when Starke and colleagues published an innovative article pointing to a novel role for VWF as a negative regulator of angiogenesis. 27 In this article, inhibition of VWF expression in human umbilical vein endothelial cells (HUVECs) using short interfering ribonucleic acid (siRNA) caused an increase in VEGF-dependent cell proliferation, migration, and tubule formation. 27 The mechanism of VWF regulation was suggested to be through two pathways with intracellular and extracellular components converging to modulate VEGF signaling (►Fig. 3).
In the extracellular pathway, VWF influences angiogenesis through interactions with integrin αvβ3. VWF is proposed to inhibit VEGF-2-induced proliferation of ECs when bound to integrin αvβ3. In HUVECs lacking VWF, an internalization of β3 from the surface of cells has been observed. The addition of extracellular VWF only partially rescued the phenotype, suggesting the presence of an intracellular pathway involving VWF. In this intracellular pathway, defective WPB formation in the absence of VWF results in improper storage of Ang-2. Thus, Ang-2 is free to escape the ECs and act on Tie-2 receptors to promote vessel destabilization. In fact, increased Ang-2 release was detected from HUVECs lacking VWF and other studies have found that Ang-2 levels are elevated in the plasma of type 3 VWD patients. 27, 82 These two pathways are interconnected with previous studies showing that Ang-2 also contributes to the degradation and internalization of αvβ3. 83 Furthermore, both pathways are known to influence VEGF signaling, 84, 85 which is enhanced when they are disturbed in the absence of VWF. 27 Starke et al also showed increased vascularization in the ears of VWF-deficient mice, further validating the role of VWF in angiogenesis.
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In its many interactions with an ever-growing list of molecules, VWF has come to be known as much more than a hemostatic protein. 6 The discovery by Starke and colleagues that VWF is a negative regulator of angiogenesis is an important contribution to the existing body of knowledge, as it provides an explanation for the vascular malformations typical of angiodysplasia found in patients with absent or abnormal VWF.
Cellular Models of VWD
The anatomic location of ECs within the vascular bed presents a considerable drawback for the routine examination of angiodysplasia and studies of VWD. As such, physicians often use clinical proxies such as malformations in the nail bed capillaries to identify vascular pathologies. 18 From a research perspective, this limitation in accessing patients' ECs has also hindered our understanding of the molecular pathology of VWD, and studies have mainly been done using non-EC-based heterologous cell systems.
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Human embryonic kidney (HEK) cells can be transfected with recombinant VWF and were preferred models over other cell types (such as COS cells) because they could form pseudo-WPBs capable of exocytosis. 88 However, these cells are not native VWF-producing cells, and important factors such as posttranslational modifications are potentially altered. 91 Furthermore, cotransfections of different mutations may not be a precise reproduction of heterozygous states in vivo. For many years, HUVECs have also been used to extensively study VWF mutations. [94] [95] [96] [97] [98] However, it is quite difficult to generate many HUVECs with specific VWF mutations and so the search for a more readily accessible source of ECs continued until 2000 when Dr. Robert Hebbel's group identified ECs that could be isolated from peripheral blood. These cells, known as blood outgrowth endothelial cells (BOECs), are derived from endothelial progenitor cells (EPCs) 99 and have significantly advanced the study of many physiological mechanisms including angiogenesis. BOECs grow with cobblestone morphology typical of mature ECs and express endothelial-specific proteins in culture. Importantly, they are representative of the donor's native vascular endothelium and maintain their differentiated phenotype through multiple passages. 27, 93, 100, 101 Of relevance to VWD studies, BOECs contain and store VWF in WPBs allowing for the examination of cellular properties of VWF such as storage and exocytosis which cannot be achieved using standard VWF functional assays. BOECs are also ideal for studies of angiogenesis, as they can be cultured to form tubules in a three-dimensional matrix and can be grown under shear stress. These cellular defects in VWF storage in VWD BOECs also extended to molecular defects in VWF synthesis and processing. 101 The heterogeneity of VWD was captured in these studies as BOECs derived from patients with similar plasma VWF profiles but different mutations had unique cellular VWF phenotypes.
VWD Studies in BOECS
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In addition to uncovering that VWF was a negative regulator of angiogenesis, Starke and colleagues also recapitulated these findings in BOECs isolated from patients with type 1, 2A, and 2M VWD. 27 BOECs from VWD patients had reduced VWF levels in culture as well as an associated increase in the release of the proangiogenic molecule Ang-2. 27 Furthermore, VWD patient-derived cells also showed a significant increase in tube formation on Matrigel, and increased VEGF-dependent proliferation and migration. 27 All of these cellular properties are characteristic of increased angiogenesis and mirror the angiogenic profile of HUVECs treated with VWF siRNA. Interestingly, no differences in angiogenesis were found between the different VWD subtypes. However, this may have been because of the small sample size. Groeneveld et al expanded on the aforementioned findings by culturing BOECs from type 1, 2A, 2B, and 3 VWD BOECs and determining their angiogenic characteristics.
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This study highlighted the complexity in distinguishing the influence of different VWF mutations on angiogenesis, given that there was great variation across both control and VWD BOECs. A key observation was the loss of migration directionality in almost all VWD BOECs. While overall VWD BOECs were not significantly more angiogenic than BOECs from controls, individual patient BOECs showed aberrantly angiogenic phenotypes when compared with controls.
Our research group is the first to successfully culture BOECs from patients of all VWD types and subtypes. Importantly, we have isolated BOECs from multiple type 3 VWD patients. 103 In line with the aforementioned studies, we have also determined the baseline angiogenic profiles of healthy non-VWD controls, and investigated the role of quantitative and qualitative VWD abnormalities on in vitro surrogates for the development of angiodysplasia. We found that overall there was great variability in the angiogenic properties of both control and VWD BOECs. Our laboratory is also interested in understanding the mechanism by which VWF HMWM modulates vessel formation. As previously mentioned, most currently available plasma-derived VWF concentrates lack VWF HMWM, while new recombinant VWF contains the full complement of multimers. BOECs present a unique opportunity to elucidate the mechanisms through which these two different VWF replacement therapies influence angiodysplasia. To accomplish this, our current studies involve treating VWD patient-derived BOECs with plasma-derived VWF and recombinant VWF that has been digested to carry varying levels of multimers and subsequently performing angiogenesis assays on these treated cells. These experiments have the potential to uncover the role of VWF HMWM in angiogenesis and identify differences in VWF replacement treatment efficacies.
Conclusion
While much research remains to be done to improve currently available treatments for patients suffering from GI bleeding, our understanding has come a long way since Dr. Erik von Willebrand first brought attention to this complex disease. VWF wears many hats in the vasculature and its role in angiogenesis provides a potential avenue for treatment for a long-fought clinical complication. These initial studies on VWD patient BOECs present a solid foundation from which future studies can be catapulted and holds promise for delineating the pathological mechanisms for different VWF mutations. 
